CGEN
$2.27
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consist...
Recent News
Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year
Compugen Ltd. (NASDAQ:CGEN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-quarter revenue of $67.3 million compared with $1.5 million in the prior year. Chief Executive Officer Eran Ophir said the company made important progress in 2025, citing the extension of its cash […]
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Compugen Ltd (CGEN) reports significant revenue increase and extends cash runway into 2029, despite challenges in trial timelines.
Compugen Ltd. Q4 2025 Earnings Call Summary
Moby summary of Compugen Ltd.'s Q4 2025 earnings call
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of +1,053.85% and +276.79%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Compugen: Q4 Earnings Snapshot
HOLON, Israel (AP) — Compugen Ltd. (CGEN) on Monday reported fourth-quarter earnings of $56.8 million. On a per-share basis, the Holon, Israel-based company said it had net income of 60 cents. The results topped Wall Street expectations.